Guru Fundamental Report for TSM

Validea's Patient Investor model, based on Warren Buffett's strategy, has assigned Taiwan Semiconductor Manufacturing Co. Ltd. (TSM) a perfect 100% rating, signaling strong interest due to its robust fundamentals and attractive valuation. The large-cap semiconductor growth stock met all key criteria, including predictable earnings, low debt, strong returns on equity and capital, and consistent free cash flow, positioning it as a long-term, predictably profitable investment.

Analysis

Taiwan Semiconductor Manufacturing Co. Ltd. (TSM) has secured a perfect 100% rating from Validea's Patient Investor model, which is based on the investment principles of Warren Buffett. This top-tier score signifies a strong conviction in the stock from a value-investing perspective, as a rating above 90% indicates significant interest. As a large-cap growth stock within the semiconductor industry, TSM successfully passed all nine of the model's fundamental and valuation criteria. Key strengths highlighted by the analysis include predictable long-term earnings, a manageable debt service level, and superior returns on both equity and total capital. Furthermore, the company demonstrates robust free cash flow generation, effective use of retained earnings, and a commitment to shareholder returns via share repurchases, satisfying all metrics for a high-quality, predictably profitable enterprise trading at a reasonable valuation according to this specific framework.

Key Decisions for Investors

• Investors with a long-term, value-oriented horizon should consider TSM a high-conviction position, as its 100% score on the Buffett-based model indicates exceptional alignment with principles of durable profitability and financial strength.
• It is prudent to monitor key metrics that underpin this rating, specifically the company's return on equity, free cash flow trends, and capital allocation policies, including share repurchases, for any signs of deviation from its current high-quality profile.
• While the fundamental analysis is overwhelmingly positive, investors should recognize this assessment is through the specific lens of Validea's 'Patient Investor' model and should ensure this GARP (growth at a reasonable price) style fits their own portfolio objectives.